Pacific Biosciences of California Accounts Payable

Pacific Biosciences of California (PACB) currently reports a accounts payable of $19M as of June 2026. That compares with $15M in the prior-year period — up 27.7% year over year. Use the charts on this page to explore Pacific Biosciences of California's accounts payable history and peer comparisons.

Pacific Biosciences of California's accounts payable increased from $15M to $19M — a 27.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pacific Biosciences of California reported $19M in accounts payable as of June 2026. That compares with $15M in the prior-year period — up 27.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $19M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pacific Biosciences of California, and consider following PACB for alerts when major investors trade the stock.

Pacific Biosciences of California is classified in the Healthcare sector. On accounts payable, it currently shows $19M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PACB with unrelated industries.